cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$1.38
$-0.02
(-1.43%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
26.52M
52-Week High
52-Week High
3.92300
52-Week Low
52-Week Low
1.30000
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization26.52M
icon52-Week High3.92300
icon52-Week Low1.30000
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
1 year ago
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced that management will participate in the following March investor conferences. Cowen 43rd Annual Health Care Conference March 6-8, 2023, at the Boston Marriott ...
Globe Newswire
1 year ago
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has ...
Business Green
1 year ago
Generation arm of UK energy giant plots expansion of wind and solar capacity in Spain, Portugal, and beyond Octopus Energy's renewables generation arm has expanded its interests in Spain, yesterday announcing an undisclosed level of investment in green energy developer FF New Energy Ventures (...
Globe Newswire
1 year ago
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. ...
Globe Newswire
1 year ago
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the companys rheumatoid arthritis medical ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.38
$-0.02
(-1.43%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00